Our Discovery Platform empowers us to identify crucial biological patterns within vast biomedical datasets. Leveraging proprietary algorithms for multi-modal single-cell analysis, we reconstruct developmental processes, gene regulatory networks, signaling pathways, and gene expression programs linked to the onset, progression, stem cell differentiation, and development of diseases.
Our Generative Biology Platform employs cutting-edge deep learning techniques to generate novel molecules with precise properties, accelerating cell therapy and drug discovery. These molecules target genes and pathways identified in our Gene Discovery platform, offering enhanced control over gene expression in specific cell types.
With our Cell Therapy Platform, we harness the power of our Generative Biology and Gene Discovery platforms to pioneer the next generation of intelligent, living biotherapeutics. Our focus initially centers on combating cancer, utilizing cell-based treatments as a transformative alternative to traditional drugs.
OUR TECHNOLOGY PLATFORM:
Innovating Breakthrough Therapies through Multiscale Biology Integration
01 DISCOVERY PLATFORM
02 GENERATIVE BIOLOGY PLATFORM
03 CELL THERAPY PLATFORM
CellComm infers cellular crosstalk that drives haematopoietic stem and progenitor cell development
Nat Cell Biol. 2022 Apr.
EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity
Cell Stem Cell 2022
The developmental stage of the hematopoietic niche regulates lineage in MLL-rearranged leukemia
JEM 2019
NetDecoder: a network biology platform that decodes context-specific biological networks and gene activities
Nucleic Acids Res 2016
Founder & Scientific Advisor
Edroaldo Lummertz da Rocha, PhD
Dr. Lummertz da Rocha’s research at the intersection of biology, computational biology and artificial intelligence has contributed to advance the fields of stem cell biology and engineering as well as cancer research. Dr. Lummertz da Rocha trained in prestigious universities, hospitals and research institutions, such as the Wyss Institute for Biologically Inspired Engineering at Harvard University, Mayo Clinic, Boston Children’s Hospital and Harvard Medical School. Dr. Lummertz da Rocha is an Assistant Professor at Federal University of Santa Catarina and Affiliate Faculty of Dell Medical School at the University of Texas in Austin. He has secured funding from the National Institutes of Health, USA, The State of Santa Catarina Research and Innovation Support Foundation (FAPESC) and the Serrapilheira Institute, Brazil, to support his laboratory’s research on hematopoiesis and cancer metastasis at the intersection with biomedical data science.
Data Scientist
Gabriela Luiz, PhD
Bioinformatician expert on NGS data analysis and development of complex pipelines. She has extensive experience in omics approaches to study parasite-host relationship and worked on several genomic and transcriptomic projects, extracting information from data using bioinformatics analyzes in Perl, R, Bash and Python languages. She also was Statistics professor for Biological Sciences and Agronomy courses and in her postdoctoral studies, she developed an integrative analysis of hematopoietic stem cell atlas using single cell transcriptomic data.
Computational Chemist
Felipe Silveira de Souza Schneider, PhD
Felipe is a skilled computational chemist with expertise in physical, quantum, and computational chemistry. He holds a Master's degree in physical chemistry and has recently completed his PhD in computational chemistry at the Federal University of Santa Catarina. Felipe has made significant contributions in the field, particularly through the development of a state-of-the-art tool that predicts chemical kinetic profiles of reaction mechanisms using first-principle quantum chemistry calculations exclusively. In addition to his background in chemistry, he is also a skilled software developer proficient in multiple programming languages, including Python, Julia, and Rust. His current research interests span across artificial intelligence and molecular design. With his diverse skill set and unwavering passion for scientific innovation, Felipe is dedicated to pushing the boundaries of knowledge.
Our team
Working at the forefront of cutting-edge research and development, our team is dedicated to pushing the boundaries of scientific discovery.
We embrace the challenges of developing novel therapies and strive to translate our collective knowledge and skills into groundbreaking solutions that have the potential to transform lives.
Selected Publications
Our mission is to redefine the very fabric of molecule development, propelling us into a new era where biotechnology is created in ways never before imagined.
Revolutionizing Molecule Discovery through Generative Biology!
We're at the forefront of cutting-edge technology, combining machine learning, biological engineering, and biotechnology to pioneer Generative Biology—an exciting new approach that revolutionizes how medicines are developed.
Cellertz Bio, a therapeutics company:
Single Cell Multi Omics
Machine Learning
Fusion of scientific disciplines
for
Enhanced R&D Productivity
Biotechnology
Data-driven, rationally designed cell therapies
Our pioneering methodology seamlessly combines advanced computational approach and rigorous experimental techniques to propel the development of the next frontier in cell therapies to treat cancer.
By exerting meticulous control over gene regulatory networks that govern crucial cell behaviors, we aspire to revolutionize the field of disease treatment.
Our primary objective revolves around identifying the optimal gene targets to modulate, allowing us to unlock the full potential of cell therapy and achieve unprecedented therapeutic outcomes.